Cargando…
Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer
SIMPLE SUMMARY: HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer (BC) is an emerging subtype of BC with promising results with antibody drug conjugate (ADC) in the metastatic setting. In the early setting, few data have been reported regarding the predictive and prognostic impact of HER2-low status in...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139240/ https://www.ncbi.nlm.nih.gov/pubmed/35626113 http://dx.doi.org/10.3390/cancers14102509 |
_version_ | 1784714813187817472 |
---|---|
author | Domergue, Camille Martin, Elodie Lemarié, Camille Jézéquel, Pascal Frenel, Jean-Sebastien Augereau, Paule Campone, Mario Patsouris, Anne |
author_facet | Domergue, Camille Martin, Elodie Lemarié, Camille Jézéquel, Pascal Frenel, Jean-Sebastien Augereau, Paule Campone, Mario Patsouris, Anne |
author_sort | Domergue, Camille |
collection | PubMed |
description | SIMPLE SUMMARY: HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer (BC) is an emerging subtype of BC with promising results with antibody drug conjugate (ADC) in the metastatic setting. In the early setting, few data have been reported regarding the predictive and prognostic impact of HER2-low status in triple-negative BC (TNBC). ABSTRACT: Purpose: Investigates the link between HER2 status and histological response after neoadjuvant chemotherapy in patients with early TNBC. Methods: We retrieved clinical and anatomopathological data retrospectively from 449 patients treated for the first time with standard neoadjuvant chemotherapy for early unilateral BC between 2005 and 2020. The primary endpoint was pathological complete response (pCR, i.e., ypT0 ypN0), according to HER2 status. Secondary endpoints included invasive disease-free survival (I-DFS) and overall survival (OS). Results: 437 patients were included, and 121 (27.7%) patients had HER2-low tumours. The pCR rate was not significantly different between the HER2-low group vs. the HER2-0 group (35.7% versus 41.8%, p = 0.284) in either univariate analysis or multivariate analysis adjusted for TNM classification and grade (odds ratio [OR] = 0.70, confidence interval [CI] 95% 0.45–1.08). With a median follow-up of 72.9 months, no significant survival differences were observed between patients with HER2-low tumours vs. patients with HER2-0 tumours in terms of I-DFS (p = 0.487) and OS (p = 0.329). Conclusions: In our cohort, HER2 status was not significantly associated with pCR in a manner consistent with data published recently on TNBC. However, the prognostic impact of HER2-low expression among TNBC patients warrants further evaluation. |
format | Online Article Text |
id | pubmed-9139240 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91392402022-05-28 Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer Domergue, Camille Martin, Elodie Lemarié, Camille Jézéquel, Pascal Frenel, Jean-Sebastien Augereau, Paule Campone, Mario Patsouris, Anne Cancers (Basel) Article SIMPLE SUMMARY: HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer (BC) is an emerging subtype of BC with promising results with antibody drug conjugate (ADC) in the metastatic setting. In the early setting, few data have been reported regarding the predictive and prognostic impact of HER2-low status in triple-negative BC (TNBC). ABSTRACT: Purpose: Investigates the link between HER2 status and histological response after neoadjuvant chemotherapy in patients with early TNBC. Methods: We retrieved clinical and anatomopathological data retrospectively from 449 patients treated for the first time with standard neoadjuvant chemotherapy for early unilateral BC between 2005 and 2020. The primary endpoint was pathological complete response (pCR, i.e., ypT0 ypN0), according to HER2 status. Secondary endpoints included invasive disease-free survival (I-DFS) and overall survival (OS). Results: 437 patients were included, and 121 (27.7%) patients had HER2-low tumours. The pCR rate was not significantly different between the HER2-low group vs. the HER2-0 group (35.7% versus 41.8%, p = 0.284) in either univariate analysis or multivariate analysis adjusted for TNM classification and grade (odds ratio [OR] = 0.70, confidence interval [CI] 95% 0.45–1.08). With a median follow-up of 72.9 months, no significant survival differences were observed between patients with HER2-low tumours vs. patients with HER2-0 tumours in terms of I-DFS (p = 0.487) and OS (p = 0.329). Conclusions: In our cohort, HER2 status was not significantly associated with pCR in a manner consistent with data published recently on TNBC. However, the prognostic impact of HER2-low expression among TNBC patients warrants further evaluation. MDPI 2022-05-19 /pmc/articles/PMC9139240/ /pubmed/35626113 http://dx.doi.org/10.3390/cancers14102509 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Domergue, Camille Martin, Elodie Lemarié, Camille Jézéquel, Pascal Frenel, Jean-Sebastien Augereau, Paule Campone, Mario Patsouris, Anne Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer |
title | Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer |
title_full | Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer |
title_fullStr | Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer |
title_full_unstemmed | Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer |
title_short | Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer |
title_sort | impact of her2 status on pathological response after neoadjuvant chemotherapy in early triple-negative breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139240/ https://www.ncbi.nlm.nih.gov/pubmed/35626113 http://dx.doi.org/10.3390/cancers14102509 |
work_keys_str_mv | AT domerguecamille impactofher2statusonpathologicalresponseafterneoadjuvantchemotherapyinearlytriplenegativebreastcancer AT martinelodie impactofher2statusonpathologicalresponseafterneoadjuvantchemotherapyinearlytriplenegativebreastcancer AT lemariecamille impactofher2statusonpathologicalresponseafterneoadjuvantchemotherapyinearlytriplenegativebreastcancer AT jezequelpascal impactofher2statusonpathologicalresponseafterneoadjuvantchemotherapyinearlytriplenegativebreastcancer AT freneljeansebastien impactofher2statusonpathologicalresponseafterneoadjuvantchemotherapyinearlytriplenegativebreastcancer AT augereaupaule impactofher2statusonpathologicalresponseafterneoadjuvantchemotherapyinearlytriplenegativebreastcancer AT camponemario impactofher2statusonpathologicalresponseafterneoadjuvantchemotherapyinearlytriplenegativebreastcancer AT patsourisanne impactofher2statusonpathologicalresponseafterneoadjuvantchemotherapyinearlytriplenegativebreastcancer |